Nanoporous foamed active compound-containing preparations based on pharmaceutically acceptable thermoplastically workable polymers
Process for the production of nanoporous foamed active substance-containing preparations, wherein the active substance is present embedded in a pharmaceutically acceptable polymer, wherein, in stage a) loading of a polymeric molding composition or a polymer melt with a propellant is effected at a pressure and at a temperature at which the propellant is in the supercritical state, in stage b) heating of the laden polymer molding compound or melt is carried out under pressure at a temperature which lies in the range from −40 to +60° C., preferably −20 to +55° C., and especially preferably 0 to +50° C. around the glass transition temperature of the unladen (prior to loading) polymeric molding compound and in stage c) a depressurization of the polymeric molding compound or melt laden in stage a) and heated under pressure in stage b) is effected out with a depressurization rate in the range from 15,000 to 200,000 MPa/sec.
1. A process for the production of nanoporous foamed active substance-containing preparations, wherein the active substance is present in a pharmaceutically acceptable polymer, wherein:
in stage a), loading of a polymeric molding compound or a polymer melt with a propellant is effected at a pressure above 10 MPa and at a temperature at which the propellant is in the supercritical state,
in stage b), heating or cooling of the laden polymeric molding compound or melt is carried out under a pressure above 10 MPa to a temperature which lies in the range from −40 to +50° C. around the glass transition temperature of the polymeric molding compound prior to loading and
in stage c), depressurization of the polymeric molding compound or melt laden in stage a) and heated or cooled under pressure in stage b) is effected with a depressurization rate in the range from 15,000 to 2,000,000 MPa/sec, wherein the temperature at the instant depressurization begins lies in the range from −40 to +50° C. around the glass transition temperature of the polymeric molding compound prior to loading and
adding the active substance to the pharmaceutically acceptable polymer before melting, during stage b), or between stage b) and stage c).
2. The process of claim 1 , wherein the loading and the heating or cooling of the polymeric molding compound or melt is performed under pressure in a pressure-resistant apparatus.
3. The process of claim 1 , wherein the depressurization is effected via valves, pressure-limiting devices or by enlargement of the cavity of the pressure-resistant apparatus.
4. The process of claim 1 , wherein the loading and the heating or cooling are performed continuously in an extruder and the depressurization is effected via a nozzle.
5. The process of claim 1 , wherein an amorphous thermoplastic is used as the pharmaceutically acceptable polymer.
6. The process of claim 1 , wherein a polymer selected from the group consisting of homo- and copolymers of N-vinyllactams is used as the polymer.
7. The process of claim 1 , wherein the pressure lies in the range from 20 to 200 MPa in stage a) and in the range from 0.01 to 1 MPa (absolute) after the depressurization.
8. The process of claim 1 , wherein carbon dioxide (CO 2 ) or dinitrogen oxide (N 2 O) is used as the propellant.
9. The process of claim 1 , wherein in stage b) heating or cooling to a temperature from −20 to +50° C. around the glass transition temperature is carried out.
10. The process of claim 1 , wherein in stage b) heating or cooling to a temperature from 0 to +40° C. around the glass transition temperature is carried out.
11. The process of claim 1 , wherein a polyether-containing graft copolymer is used as the pharmaceutically acceptable polymer.
12. The process of claim 11 , wherein a polyether-containing graft copolymer, obtained by radical polymerization of i) 30 to 70 wt. % N-vinyllactam, ii) 15 to 35 wt. % vinyl acetate and ii) 10 to 35 wt. % of a polyether, is used as the pharmaceutically acceptable polymer.
13. The process of claim 1 , wherein a copolymer of 50 wt. % methacrylic acid and 50 wt. % ethyl acrylate is used as the pharmaceutically acceptable polymer.